Alerts will be sent to your verified email
Verify EmailBAFNAPH
|
Bafna Pharmaceutical
|
KRM Ayurveda
|
Haleos Labs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
0.0 | 56.82 % | 9.86 % |
|
5yr average Equity Multiplier
|
3.77 | 3.75 | 2.28 |
|
5yr Average Asset Turnover Ratio
|
0.42 | 1.65 | 0.85 |
|
5yr Avg Net Profit Margin
|
-36.55 % | 9.8 % | 4.95 % |
|
Price to Book
|
10.39 | 0.0 | 2.33 |
|
P/E
|
47.86 | 25.65 | 28.73 |
|
5yr Avg Cash Conversion Cycle
|
0.18 Days | -112.83 Days | -6.07 Days |
|
Inventory Days
|
87.65 Days | 10.11 Days | 78.84 Days |
|
Days Receivable
|
132.64 Days | 42.11 Days | 56.81 Days |
|
Days Payable
|
210.48 Days | 146.84 Days | 142.69 Days |
|
5yr Average Interest Coverage Ratio
|
-5.68 | 9.96 | 4.18 |
|
5yr Avg ROCE
|
-11.61 % | 35.19 % | 11.01 % |
|
5yr Avg Operating Profit Margin
|
-21.98 % | 16.43 % | 10.73 % |
|
5 yr average Debt to Equity
|
1.41 | 1.89 | 0.52 |
|
5yr CAGR Net Profit
|
12.0 % | 9.75 % | 8.2 % |
|
5yr Average Return on Assets
|
-16.11 % | 15.05 % | 4.32 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 69.15 % | 72.11 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-15.0 % | 0.0 | 1.79 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bafna Pharmaceutical
|
KRM Ayurveda
|
Haleos Labs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|